PET Drugs May Get Shorter Path To FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
For positron emission tomography drugs with low levels of use that are needed to diagnose rare conditions, an expanded access IND may be the best regulatory pathway.
You may also be interested in...
PET Drugs Without An IND Get Three More Years For Studies Under FDA Guidance
Q&A document from agency says sponsor does not have to use the same manufacturing process as the reference listed drug.
FluoroPharma’s Bet On Next-Gen Molecular Imaging Agents
Molecular imaging’s technological advances are impressive, but getting the business model right and investors on board has been hard for start ups in the field. FluoroPharma CEO Thijs Spoor believes his company, which has several cardiovascular imaging agents in clinical trials, is on the right track and ripe for partnerships.
PET Drug Research Still In FDA's Enforcement Crosshairs As Columbia University Draws Warning Letter
While FDA is trying to make the approval process for PET drugs easier, that doesn't spare sponsors the responsibility to follow the rules.